Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP by Marie-Josée J Mangen et al.
STUDY PROTOCOL Open Access
Rationale and design of the costs, health status
and outcomes in community-acquired pneumonia
(CHO-CAP) study in elderly persons hospitalized
with CAP
Marie-Josée J Mangen1*, Marc JM Bonten1,2 and G Ardine de Wit1,3
Abstract
Background: Vaccine effectiveness is usually determined in randomized controlled trials (RCT) and if effective,
additional information, e.g. on cost-effectiveness, is required to allow evidence-based decision making. A prerequis-
ite for proper health economic modelling is the availability of good quality data on health care resources use,
health outcomes and quality-of-life (QoL) data. The “Collecting health outcomes and economic data on hospitalized
Community Acquired Pneumonia (CHO-CAP) – a prospective cohort study” is executed alongside the Community
Acquired Pneumonia Immunization Trial with Adults (CAPiTA trial) to capture health outcomes and economic data
of elderly hospitalized with CAP and matched controls without CAP.
Methods/Design: CAPiTA is a placebo-controlled double-blind RCT evaluating the effectiveness of a 13-valent con-
jugated pneumococcal vaccine in preventing vaccine-type pneumococcal CAP in 84,496 elderly in the Netherlands.
Participants of CAPiTA, who consented and provided information on health status (EQ-5D) and socio-demographic
background at the time of vaccination, constitute the source population of CHO-CAP and are eligible for the nested
matched cohort study. CHO-CAP patients hospitalized with CAP form the “diseased” cohort and the “non-diseased”
cohort consists of unaffected persons (i.e. no CAP). Observations in the diseased cohort and in matched controls
from the non-diseased cohort are used to determine excess costs and QoL changes attributable to CAP.
Based on an estimated 2,000 CAPiTA participants being hospitalized with CAP and an assumed CHO-CAP participa-
tion rate of 30% of all CAPiTA participants (±25,000), 600 CAP episodes are expected among CHO-CAP participants
(the “diseased” cohort). For each patient with CAP, two non-diseased CHO-CAP subjects will be selected from the
CHO-CAP cohort, with matching for age, gender and EQ-5D baseline-score. Data on healthcare and non-healthcare
resources use, quality-of-life (using EQ-5D and SF-36 questionnaires) and selected health outcomes will be collected
at 0, 1, 6 and 12 months after hospitalization for CAP.
The CHO-CAP study was approved by the Central Committee on Research involving Human Subjects in the
Netherlands.
Discussion: With an expected 600 CAP episodes this study will be one of the biggest prospectively studied cohorts
of hospitalized elderly with CAP with regard to resources use and Qol data. Strengths of this study further include
collection of out-of-pocket costs of patients and productivity losses of both patients and their caregivers and the
follow-up period of up to one year post-discharge. This study is therefore expected to add more in-depth know-
ledge on the short and longer term outcomes of pneumonia in elderly.
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Background
The Community Acquired Pneumonia Immunization Trial
in Adults (CAPiTA) is a randomized placebo-controlled
double-blind trial to determine the efficacy of a 13-
Valent Pneumococcal Conjugate Vaccine (13vPnC) in the
prevention of vaccine-serotype pneumococcal community-
acquired pneumonia (CAP) and invasive pneumococcal
disease (IPD) [1]. Within the CAPiTA trial, 84,496 volun-
teers aged 65 and over, dispersed over the Netherlands, re-
ceived 13vPnC or placebo in a single-dose vaccine between
October 2008 and 31 January 2010. Objectives with regard
to efficacy, safety and health outcomes have been described
elsewhere [1]. In case of clinical vaccine effectiveness for
CAP prevention, drug-licensing and governmental bodies
will require detailed information on the cost-effectiveness
of this vaccine in elderly in order to decide whether re-
stricted (financial) resources have to be invested in wide-
spread use of this vaccine [2,3]. If clinically effective, this
vaccine might reduce healthcare resource use, increase
quality-of-life and reduce mortality in elderly. These effects
stretch beyond the hospitalization period, as covered in the
CAPiTA trial.
There are few recent cost estimates for CAP, and none
of them have been derived from Dutch patients [4]. The
few prospectively conducted studies (e.g. [5-8]) considered
only direct healthcare costs during hospitalisation, had no
or limited follow-up post-discharge, and most had a rela-
tive small sample size [7,8]. Larger cost studies were
mainly retrospective, focussing mostly on direct healthcare
costs of patients hospitalised with CAP, with no or limited
follow-up post-discharge [4,7,9-18]. However, since CAP
may influence the occurrence of other disease events (i.e.
stroke and other cardiovascular events [19,20]) in the
post-discharge period, it is important to include all health-
care resource use, not only resource use related to the
index CAP episode. Also, post-discharge mortality is non-
negligible in this population [21]. It is therefore important
to have a follow-up period that is much longer than the
immediate CAP-related hospitalization period when esti-
mating costs associated with CAP.
The “Costs, Health status and Outcomes of CAP”
study (CHO-CAP), in full “Collecting health outcomes
and economic data on hospitalized Community-
Acquired Pneumonia – a prospective cohort study”, is
designed to prospectively determine health outcomes,
quality-of-life (QoL) and costs associated with CAP for a
period of 12 months after hospitalization due to CAP.
Objective
CHO-CAP comprises the collection of cost data and
quality-of-life data in elderly with and without CAP. The
primary objectives are:
1. To determine, during a 12 month follow-up period,
differences in quality-of-life of elderly with and
without CAP.
2. To determine, during a 12 month follow-up period,
differences in resource use (healthcare and non-
healthcare) in elderly with and without CAP.
The secondary objective is to describe the baseline
health status and quality-of-life of a community-dwelling
elderly population eligible for participation in the CAPiTA
study.
Methods/Design
Ethical and governance approval
Approval was granted by the Central Committee on
Research involving Human Subjects (in Dutch Centrale
Commissie Mensgebonden Onderzoek (CCMO)), Ref:
NL.24770.041.08.
Study design
CHO-CAP consists of a baseline cohort and a nested
matched-cohort study, both executed in parallel to the
CAPiTA trial.
Baseline cohort
The study population included in the CAPiTA trial con-
sists of 84,496 community-dwelling persons 65 years and
older randomized to receive 13vPnC or placebo (for details
of inclusion and exclusion criteria see Hak et al. [1]). All
patients included were eligible to participate in the CHO-
CAP study. For the baseline cohort, CAPiTA participants
were approached at the vaccination centre for participation
in CHO-CAP. After inclusion in the CAPiTA study and re-
ceipt of study vaccination, participants received written in-
formation on the CHO-CAP study. Subjects were asked to
fill in a questionnaire and to return it, together with a
signed informed consent form, in a pre-stamped envelope.
Those who did form the source population (i.e. baseline
CHO-CAP cohort) are eligible for participation in the
nested matched cohort study (see Figure 1). Subjects
returning their questionnaire without informed consent
Mangen et al. BMC Infectious Diseases 2013, 13:597 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/597
form were contacted a second time with the request to also
return a signed informed consent.
Nested matched cohort study
As part of the CAPiTA trial, patients with a clinical suspi-
cion of CAP are tracked in 56 Dutch sentinel hospitals.
The duration of follow-up within CAPiTA is defined by
the number of primary endpoints captured (i.e. 130 first
CAP episodes caused by vaccine-type S. pneumoniae sero-
types). It is expected that around 2,000 CAP episodes will
occur within the study population [1]. Assuming a re-
sponse rate of ~30%a for the baseline questionnaire, we
expected approximately 600 first CAP episodes among
CHO-CAP participants. Local research nurses in sentinel
hospitals notify the CHO-CAP team of newly admitted
CAPiTA patients with a clinical suspicion of CAP directly
after hospital admission and at the time of discharge. After
discharge, eligible patients (i.e. CHO-CAP participants)
will be asked to participate in the prospective cohort study
for a period of one year. Patients are informed (orally and
by written information) that participation involves one
interview during a home visit, with three subsequent ques-
tionnaires to be completed during the 12 month period.
Patients again provide informed consent upon inclusion in
the prospective cohort study. Exclusion criteria for the
prospective cohort study are hospitalization for a second
(or further) hospitalization for CAP related complaints,
inability to complete questionnaires, or a recent diagnosis
of malignancy as the study was considered too burden-
some for this latter group.
For each patient with CAP in the prospective cohort
study (“diseased” cohort), two matched unaffected subjects
(i.e. no CAP episode until the time of matching) will be se-
lected from the baseline population for inclusion in the
“non-diseased” cohort (see Figure 1). Matching is based
on age (same age, with allowance of 3 years age differ-
ence), gender and baseline health status (same EQ-5D
score [22], with maximum allowance of 5 percent points
difference). Expectations are that both in the short-term
and the medium term, CAP patients consume more med-
ical resources, require more (in)formal help, might experi-
ence more trouble to get back to their daily activities, and
have a lower quality-of-life than their non-diseased peers.
Furthermore, mortality, both within-hospital as during the
12 months follow-up period, is expected to be higher in
CAP patients than in controls.
The inclusion of two unaffected controls increases the
validity of study results and diminishes the risks from
loss to follow-up. Exclusion criteria for controls are ad-
mission to hospital for a CAP episode since vaccination,
inability to complete questionnaires, or having a recently
diagnosed malignancy, as the study was considered too
burdensome for the latter group. Controls also provide
informed consent at start of follow-up.
85,000 CAPiTA participants
With baseline EQ-5D score 
and consent
~25,500 persons 
= CHO-CAP baseline cohort

















If consent, 2 controls 






Contact at 0, 1, 6 and 
12 months. 
If consent, included in 
diseased cohort.
Contact at 0, 1, 6 and 
12 months
Information on mortality, withdrawal, loss to follow-up and some information on socio-demographic data and 
comorbidity from main trial for all participants;
Information on hospital resources used from the Etio-CAP substudy and main trial CAP cases.
EQ- (October 2008 – January 2010)5D questionnaire for baseline measurement 
Figure 1 Flow chart of the CHO-CAP study with different (sub-)cohorts and anticipated number of participants.
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Data collection
Baseline CHO-CAP cohort study at time of vaccination
At the time of vaccination subjects were asked to pro-
vide information on:
 health status (5 item EQ-5D instrument [22] (see
Table 1)),
 socio-demographic status (i.e. education and current
living situation)
 self-reporting of previous manifestations of stroke or
other cardiovascular disease events.
After receipt of the completed baseline questionnaire,
CAPiTA participant ID, informed consent, socio-
demographic data, and EQ-5D index value for health
status (see below) were registered in the CHO-CAP
database, with linkage to the CAPiTA database for age,
gender and place of residence/region. Regular updates to
adjust for changes in place of residence or to include
loss-to-follow up (e.g., due to death), take place.
Following the standards set up by the Euroqol organisa-
tion, the developers and owners of the EQ-5D instrument
[22], the 5-items from the EQ-5D questionnaire were
transferred into a single value between 0 (worst imagin-
able health status) and 1 (best imaginable health status)
[23].
Nested matched cohort study
Each identified CHO-CAP participant hospitalized with
CAP and interested in participation in the prospective
“diseased” cohort is visited at home by a trained inter-
viewer. Informed consent is obtained during this home
visit. If consent is given, questions on health status, co-
morbidities, current living situation and healthcare re-
sources used before hospital admission are collected (see
details in Table 2). A diary for own recording of health-
care resource use and other out-of-pocket expenses in
the forthcoming period (i.e. one month) is explained and
provided. Healthcare resources used during hospital ad-
mission (i.e. length of hospitalization, medication, diag-
nostics, interventions (e.g. surgery), complications, ICU
admission) is collected from hospital databases by local
trial nurses.
Similar procedures are followed for the controls. An
identified and eligible control who expressed interest to
participate at the time of vaccination is visited at home.
If consent is given, a questionnaire similar to that
administered in the “diseased” cohort is provided (see
details in Table 2).
In both the “diseased” and “non-diseased” cohorts, fur-
ther data is collected on 1, 6 and 12 months after the ini-
tial home visit. Questionnaires are send by post, with the
request to fill-in and send back within a week. If no re-
sponse is received, participants are contacted by phone.
This follow-up questionnaire addresses current living
conditions, quality-of-life, co-morbidities and healthcare
resources used (Table 2). A new diary for recording of
healthcare use and other out-of-pocket expenses in the
forthcoming period is provided once the questionnaire has
been returned.
Sample size
As CHO-CAP was designed and executed in parallel to
the CAPiTA study, the sample size is - to a large extent –
determined by the infrastructure of that study. The sample
size of the different cohorts in CHO-CAP is determined
by the expected number of CAP episodes occurring in the
CAPiTA trial (i.e. ~ 2,000 cases, see [1]), as well as by the
response rate obtained for the baseline CHO-CAP ques-
tionnaire and the willingness of patients with CAP and
controls to participate in the nested matched cohort study.
It is expected that at most 600 CAP episodes will be in-




The health status as observed in the baseline cohort and at
different follow-up moments in the “diseased” and “non-
diseased” cohorts will be presented, with and without
stratification for age, gender and/or baseline EQ-5D scores.
Table 1 The 5-item EQ-5D questionnaire (Source: [22])
Mobility
I have no problems in walking about □
I have some problems in walking about □
I am confined to bed □
Self-care
I have no problems with self-care □
I have some problems washing or dressing myself □
I am unable to wash or dress myself □
Usual activities (e.g. work, study, housework, family or leisure
activities)
I have no problems with performing my usual activities □
I have some problems with performing my usual activities □
I am unable to perform my usual activities □
Pain/discomfort
I have no pain or discomfort □
I have moderate pain or discomfort □
I have extreme pain or discomfort □
Anxiety/depression
I am not anxious or depressed □
I am moderately anxious or depressed □
I am extremely anxious or depressed □
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Table 2 Data collection in matched cohort-studya
Cohort Diseased cohort (i.e. CAP









at 1, 6 and
12 months
Data collected:
Demographic data ➣ Current living situation ➣ Current living situation ➣ Current living
situation
Quality-of-life data
➣ 5-item EQ-5D instrument & VAS [22] ➣ As on day of interview As on day of interview As on day of
interview
➣ Referring back to worst
moment of CAP episode
➣ Referring back to time
previous to CAP episode









➣ 28-item standard list of major comorbid diseases developed
by Statistics Netherlands
➣ 28-item standard list of major
comorbid diseases




➣ Medication used ➣ Previous to hospital
admission to treat CAP;
n.a.b ➣ Since last
contact moment;
➣ GP; emergency department and other medical specialist
consultations (phone; office and home consultation(s))
➣ Previous to hospital
admission to treat CAP;
n.a.b ➣ Since last
contact moment;
➣ Outpatient visit(s) and treatment(s) n.a.b n.a.b ➣ Since last
contact moment;
➣ Hospital admission(s) and treatment(s) n.a.b n.a.b ➣ Since last
contact moment;
➣ Institutional care admission(s) others than hospital n.a.b n.a.b ➣ Since last
contact moment;
Home care
➣ Professional home care used ➣ Previous to hospital
admission during the CAP
episode?




Productivity losses due to absence from patient/control from unpaid work (including replacement)
➣ Is unpaid work conducted on a regular base. ➣ Previous to CAP hospital
admission
n.a.b ➣ Since last
contact moment;
➣ Absent from unpaid work: For how long. Who took the
work over?
➣ Previous to hospital
admission during the CAP
episode?
n.a.b ➣ Since last
contact moment;
Productivity losses due to absence of caregiver(s) from (un)paid work
➣ Informal home care used: By who? And for how long? ➣ Previous to hospital
admission during the CAP
episode
n.a.b Since last contact
moment;
Travel costs:
Method of transport and cost ➣ To hospital when admitted
with CAP
n.a.b n.a.b
➣ After discharge from hospital
to home/nursing home
n.a.b n.a.b
Other cost/out-of-pocket expenses (open question) n.a.b n.a.b ➣ Since last
contact moment;
Note:
a) Questionnaires (in Dutch) are available on request from first author.
b) n.a. = not applied.
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Following guidelines from the SF-36 developers [24,25],
SF-36 results will be presented in a decomposed manner, i.
e. for the 8 sub-scales and for the 2 composite summary
scores for physical and mental functioning. We will calcu-
late mean, median and the 5th, 25th, 75th and 95th per-
centiles for all QoL data.
The observed use of healthcare and other resources for
CAP patients and controls over time will be described, in
quantity (volumes of resource use) and in costs, following
Dutch guidelines for health economic studies [26]. Costs
will be presented, both undiscounted and discounted
using different discount rates. Decomposed in volumes of
resources use and associated costs, results will be pre-
sented as mean, median and the 5th, 25th, 75th and 95th
percentile.
Statistical analysis
The main analysis will be the comparison of the matched
cohort of CAP patients with the non-diseased controls.
Univariate analysis will be applied in first instance. De-
pending on the distribution of data, we will use t-test or
non-parametric tests (e.g. nonparametric bootstrap) to es-
timate the difference between both cohorts. Univariate
analysis is also applied when analysing the health status
for age groups within the baseline population. Here,
ANOVA tests will be used as well. Where dealing with
mainly normally distributed data, OLS (Ordinary least
squares) regression is applied. Otherwise, the generalized
linear model (GLM) will be preferred.
Discussion
The infrastructure of the CAPiTA trial offers a unique op-
portunity for prospective collection of health outcomes,
QoL and cost data of patients hospitalized with CAP. Such
data will facilitate the construction and validation of
health economic models on cost-effectiveness and cost-
utility of 13vPnC in the future, should this become neces-
sary if vaccine efficacy and safety is demonstrated.
One of the limitations of the current study is that we
might mainly reach the ‘healthier’ part of the community-
dwelling CAPiTA participants, as older and more diseased
subjects may be less willing to participate in additional re-
search projects next to the main CAPITA trial. To gain
insight into this possible bias, we will compare the base-
line demographic data of the CHO-CAP cohort popula-
tion with the larger CAPiTA population. Further, data
gathered within the CAPiTA-study will enable us to com-
pare CAP cases from the current CHO-CAP cohort with
all CAP cases, for instance with regard to duration of
hospitalization and occurrence of complications.
With an expected 600 CAP episodes we expect to con-
stitute one of the biggest prospectively studied cohorts of
hospitalized elderly with CAP with regard to resources
use and QoL data. Strengths of this study further include
collection of out-of-pocket costs of patients and product-
ivity losses of both patients and their caregivers and the
follow-up period of up to one year post-discharge. Our
study is expected to add more in-depth knowledge on the
short and longer term outcomes of pneumonia in elderly.
Endnote
aCommercial marketing questionnaires without any in-
volvement of the participants normally reach a response
rate around 20%. Healthcare questionnaires are known to
obtain slightly higher response rates, whereby the greater
the involvement, the higher the response rate. Given their
previous participation in the CAPiTA study we expected
some involvement from these participants for the current
study, and therefore a response rate of 30% was expected
to be feasible.
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